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cl-l1 and cl-K1 exhibit Widespread 
Tissue Distribution With high 
and co-localized expression 
in secretory epithelia and Mucosa
Soren W. K. Hansen1*, Josephine B. Aagaard 1, Karen B. Bjerrum1, Eva K. Hejbøl2,  
Ole Nielsen2, Henrik D. Schrøder 2, Karsten Skjoedt1, Anna L. Sørensen1,  
Jonas H. Graversen1 and Maiken L. Henriksen1
1 Institute of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark, 2 Department  
of Pathology, Odense University Hospital, Odense, Denmark
Collectin liver 1 (CL-L1, alias collectin 10) and collectin kidney 1 (CL-K1, alias collectin 11) 
are oligomeric pattern recognition molecules associated with the complement system, 
and mutations in either of their genes may lead to deficiency and developmental defects. 
The two collectins are reportedly localized and synthesized in the liver, kidneys, and 
adrenals, and can be found in the circulation as heteromeric complexes (CL-LK), which 
upon binding to microbial high mannose-like glycoconjugates activates the complement 
system via the lectin activation pathway. The tissue distribution of homo- vs. heteromeric 
CL-L1 and -K1 complexes, the mechanism of heteromeric complex formation and in 
which tissues this occurs, is hitherto incompletely described. We have by immunohisto-
chemistry using monoclonal antibodies addressed the precise cellular localization of the 
two collectins in the main human tissues. We find that the two collectins have widespread 
and almost identical tissue distribution with a high expression in epithelial cells in endo-/
exocrine secretory tissues and mucosa. There is also accordance between localization 
of mRNA transcripts and detection of proteins, showing that local synthesis likely is 
responsible for peripheral localization and eventual formation of the CL-LK complexes. 
The functional implications of the high expression in endo-/exocrine secretory tissue and 
mucosa is unknown but might be associated with the activity of MASP-3, which has a 
similar pattern of expression and is known to potentiate the activity of the alternative 
complement activation pathway.
Keywords: collectin, complement system, 3Mc syndrome, mucosal immunology, innate immunity
inTrODUcTiOn
The innate immune system is a first line of defense and plays major roles in preventing microorga­
nisms in settling and becoming pathogens, and also in the mounting of suitable immune responses 
against eventual pathogens. It often relies on recognition and binding to pathogen­associated 
molecular patterns by host pattern recognition molecules (PRMs). Based on an often observed 
association between microbial evasion of the complement system and pathogenicity (1), the 
complement system appears to play substantial roles in the innate immune system. The overall 
antimicrobial functions of the complement system are to tag microorganisms for elimination 
by phagocytes, to initiate inflammation and to lyse the microorganisms. The complement system 
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is a “self­amplificative“ cascade system, mainly found in the 
blood, and includes several PRMs; among which some activate 
a pathway known as the lectin activation pathway, via activation 
of serine proteases known as MBL­associated serine protease 
(MASP­1, ­2, and ­3) (2, 3). Mannan­binding lectin (MBL) is 
probably the most studied PRM of the lectin activation pathway 
and binds to mannose­rich glycoconjugates on the surface of 
microorganisms, initiating complement activation. In humans, 
MBL deficiency may increase susceptibility toward infections 
in certain situations but not in general (4), most likely contributed 
by coincidental activation of different complement activation 
pathways by a given microorganism.
Collectin liver 1 (CL­L1) and collectin kidney 1 (CL­K1) are 
“MBL­like” proteins that also are found in the circulation in 
association with MASPs and with specificity toward mannose­rich 
glycoconjugates and negatively charged molecules (5–10). In the 
circulation they can be found as heteromeric molecules, referred 
to as CL­LK, with superior complement abilities via MASP­2 in 
comparison with their respective homomers (11). They are both 
synthesized in the liver by hepatocytes, in the adrenal glands and in 
the tubules of the kidney, in addition to other tissues as well (5–7). 
On the protein level, human CL­K1 has been associated with the 
same tissues, while human CL­L1 in the original study only was 
associated with hepatocytes, however, without examination or 
exclusion of other tissues and cells (6, 7). Among normal healthy 
populations of different origins, they both constitute average 
serum concentrations of 250–450 ng/ml, with a clear correlation 
between levels of CL­L1 and CL­K1, supportive of heteromeric 
complexes between the two or similar regulation (7, 12–15). 
The liver and adrenals are due to their endocrine nature and a 
relative high synthesis of mRNA believed to be the major organs 
contributing to the CL­L1 and CL­K1 found in the circulation. 
Partly due to the recently described characterization and associa­
tion with complement, little is known about their roles in vivo. In 
a recent work using mice deficient of CL­K1, Wakamiya and col­
leagues showed that CL­K1 protected mice against Streptococcus 
pneumonia infections induced via nasal inoculation (16). 
However, in another work there was no protective effect of CL­K1/ 
CL­LK in a mouse model for infection by Mycobacterium tuber-
culosis (17). CL­K1 has been shown to bind with relative high 
affinity to the disaccharide Man(α1­2) and to negatively charged 
molecules, including nucleic acid ligands, and may also play a role 
in the opsonization of apoptotic cells by recognizing a combina­
tion of carbohydrate and nucleic ligands (10, 18).
Recently, it was demonstrated that CL­K1­deficient mice 
partly were protected against destructive complement­mediated 
inflammatory responses in post ischemic kidneys and that 
CL­K1 further promoted development of renal fibrosis in the 
tubules (19, 20).
CL­K1 and CL­L1 are not regulated significantly by inflam­
matory stimuli. Their plasma/serum levels do not correlate with 
increased levels of traditional inflammatory mediators, including 
CRP and TNF­alpha (8, 9).
The two collectins play apparently also important roles for 
embryogenesis. Deficiency of CL­K1 or CL­L1 leads in humans 
to a rare congenital developmental syndrome known as 3MC 
(alias Malpuech facial clefting syndrome), an effect that the two 
collectins share with MASP­3. It has been shown that CL­K1 and 
CL­L1 may act as attractants and guidance cue for neural crest 
cells, although the precise mechanism for embryonic involve­
ment remains to be elucidated (21, 22).
A functional and complete activation of the complement 
system involves many complement factors and is in general only 
associated with the effect in the circulation or at inflamed sites, 
where blood components gain access. Most tissue expresses 
certain complement components, e.g., the lung and the intes­
tinal system (23, 24). At such sites the complement system is 
believed to be partially functional or to mediate activation when 
inflammation progresses. In the quest of elucidating the func­
tion of CL­L1 and CL­K1, we characterized their localization 
in human tissues. It appears that the previously characterized 
sites of localization in the circulation, adrenals, liver, and kidney, 
may have disparaged a compelling localization in especially exo­
crine/endocrine tissues and mucosa, suggestive of that CL­L1, 
CL­K1, and CL­LK may play roles in the periphery as well.
MaTerials anD MeThODs
general reagents and Buffers
Unless otherwise stated, reagents were obtained from Sigma­
Aldrich, Denmark. Phosphate­buffered saline: 10 mM Na2HPO4, 
140  mM NaCl, and 2.7  mM KCl pH 7.4. Tris­buffered saline 
(TBS): 10 mM Tris and 145 mM NaCl. TNT buffer: 0.10 M Tris, 
0.15 M NaCl, and 0.05% Tween 20 pH 7.5.
generation of Mabs against cl-l1 and 
cl-K1
CL­LK was purified from outdated plasma by calcium sensitive 
immunoaffinity chromatography as previously described (25). 
Purified CL­LK (50  µg) was used for s.c. immunizations of 
outbred NMRI female mice using Gerbu as adjuvant. Three days 
before the fusion, mice were boosted (i.p.) with the same amount 
of CL­LK. The fusion between spleen cells obtained from the 
CL­LK immunized mice and myeloma cells (Sp2) was performed 
using polyethylene glycol essentially as described previously in 
Ref. (26). Positive clones were identified by ELISA using micro­
titer plates coated with either purified recombinant CL­K1 or 
CL­L1 expressed in CHO cells as full­length molecules without 
any tags. Cells from the positive wells were recloned at least thrice 
by the limiting dilution method. For antibody production and 
subsequent purification, hybridomas were grown and allowed to 
express the MAb in Hybridoma­SFM (Invitrogen). Monoclonal 
antibodies were purified by means of affinity chromatography 
using a HiTrap Protein G HP column (GE Healthcare) under 
previously described conditions and elution with 50 mM glycine, 
pH 2.3 (27). The two antibodies, MAb 11­1 (anti­CL­K1) and 
MAb 16­13 (CL­L1), which were superior in specificity and IHC 
sensitivity and applied in the following studies, were both of the 
isotype IgG1kappa.
sDs-Page and Western Blotting
SDS­PAGE was performed according to the method of 
Laemmli (1970) using pre­casted NuPAGE 4–12% Bis­Tris gels 
FigUre 1 | Structure of CL-LK and antibody specificity. (a) Schematic illustration of the domain organization of CL-L1 and CL-K1 polypeptide chains. The symbol 
“*”on the CL-L1 polypeptide chain represent two N-linked glycosylation sites in the carbohydrate recognition domain. CL-K1 is found in the circulation in the form  
of two isoforms: CL-K1a represents full-length and CL-K1d represents an alternative spliced form devoid of a part of the collagen-like region. (B) Subunit of CL-LK 
and oligomeric structures. A total of three polypeptide chains of CL-K1 and CL-L1 join to form a heteromeric subunit, which may further oligomerize into structures 
ranging from dimers to hexamers of subunits, here illustrated by a tetramer. (c) Analysis of purified CL-LK by SDS-PAGE and visualization by silver staining. The 
three bands of CL-L1 represent non-, partially, and fully glycosylated forms of CL-L1. (D,e) Specificity of monoclonal antibodies by Western blotting of serum under. 
reducing conditions and visualization by ECL. (F–h) SPR analyses of monoclonal antibodies with immobilized CL-K1, CL-L1, and CL-LK as antigen, respectively. 
MAbs 16-13 (--) and 11-1 (---) were analyzed for binding to immobilized purified CL-L1 (F), CL-K1 (g), or CL-KL (h) MAb using concentrations ranging from 0.1 to 
10 µg/ml.
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(Invitrogen) and MES or MOPS SDS running buffer (Invitrogen) 
(28). Proteins were transferred to the Hybond­P polyvinylidene 
fluoride membrane (GE Healthcare) (29). The membrane was 
blocked in 5% non­fat dried milk and 0.1% HSA, and incubated 
with primary monoclonal antibodies (0.5 µg/ml). Subsequently, 
the membrane was washed and incubated with HRP­conjugated 
rabbit anti­mouse antibody diluted (1:20,000) accordingly to the 
manufacturer’s recommendation (Dako, Denmark) and devel­
oped by means of the ECL plus Western blotting detection kit 
(GE Healthcare). For specificity testing of applied antibodies, 1 µl 
of serum was applied to the gel per 4 mm well width.
surface Plasmon resonance
Binding characteristics of the monoclonal antibodies, 11­1 
and 16­13, was investigated by SPR on a Biacore 3000 instru­
ment (Biacore, Sweden) with immobilized CL­K1, CL­L1, and 
CL­LK on a CM5 chip. The proteins were immobilized on EDC/
NHS­activated flow cells by injecting the collectin (10 µg/ml) in 
10 mM acetate pH 5.0 to a surface density ranging from 0.028 
to 0.042 pmol/mm2. One M of ethanolamine, pH 8.5 was used 
for capping. For binding experiments antibodies were diluted in 
running buffer (10 mM HEPES, 150 mM NaCl2, 5 mM EDTA, 
and 0.005% Tween­20 pH 7.4) in a range from 2.08 to 166 nM. 
Each sample (40  µl) was injected with a flow rate of 5  µl/min. 
Regeneration was obtained for antibody 11­1 by injection of two 
cycles of 10 µl: 10 mM glycine, 20 mM EDTA, 500 mM NaCl, 
and 0.005% Tween­20 pH 4.0. Regeneration was obtained for 
antibody 16­13 by injection of two cycles of 10  µl: 100  mM 
glycine, 5 mM EDTA, 500 mM NaCl, and 0.05% Tween­20 pH 
3.0. BIAevaluation software 4.0.1 was used for analysis of the 
data. The apparent dissociation constants were found by fitting 
the curves to a 1:1 binding model. All experiments were as a 
minimum conducted as triplicates of duplicates.
mabs’ impact on ligand Binding and 
complement activation
MaxiSorpTM 96­well plate were coated with DNA (2  µg/ml, 
cat. no. D2001, Sigma­Aldrich) or mannan (20  µg/ml, cat. no. 
M3640, Sigma­Aldrich) in 1  M NaCl. Purified native CL­LK 
(0.25 µg/ml) was pre­incubated in non­adsorbent wells for 1 h at 
RT in the presence of serum, mannose, or mAbs, diluted twofold 
from 10%, 200  mM, or 2  µg/ml respectively, and subsequently 
incubated on ligand­coated plates for 4  h. Bound CL­LK was 
detected using biotin­labeled anti­CL­K1 mAb (0.5 µg/ml, Hyb 
14­29, N­terminal specific) and streptavidin­HRP (0.1  µg/ml). 
Samples were diluted in TBS (20 mM Tris, 125 mM NaCl, pH 7.4) 
with 2 mM CaCl2, 0.05% Tween 20, and 0.1% BSA. For assessing 
CL­LK­mediated complement activation plates were prepared 
FigUre 2 | Characterization of mAbs’ impact on the ligand-binding and 
complement activity mediated by CL-LK. (a) Impact on ligand-binding. 
CL-LK was incubated on ligand-coated plates (mannan or DNA) in the 
presence or absence of the mAbs used for IHC (mAb 11-1 and mAb 16-13), 
mannose, or serum (known to interfere with the binding of CL-LK to ligands). 
mAb 131-1 (anti-MBL) was included as control. Bound CL-LK was detected 
with biotinylated mAb-anti-CL-K1 (compatible with the applied mAbs) and 
HRP-streptavidin. (B) Impact on CL-LK-mediated complement activation. 
Prior to incubation with MASP-2 and C4, plates were prepared with CL-LK 
and coated ligands (mannan or DNA) as above. Deposition of C4b was 
detected with biotin-labeled anti-C4b mAb and HRP-streptavidin. The results 
shown are representative of three independent experiments. Error bars refer 
to max and min of triplicate measurements. None of the tested mAbs 
interfered with ligand binding or complement activation. CL-LK binding to 
mannan and DNA occurs via two separate binding site, and the latter is not 
inhibited by mannose, whereas uncharacterized blood components inhibit 
both types of interaction (10, 11).
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as above. Purified native CL­LK (2  µg/ml) was pre­incubated 
in non­adsorbent wells with mAbs (0.5 or 4 µg/ml) or mannose 
(50 or 200 mM) at 37°C for 1 h, and subsequently incubated on 
ligand­coated plates at 37°C overnight. Wells were washed and 
incubated with recombinant MASP­2 (0.25  µg/ml for 3  h) fol­
lowed by incubation with purified C4 (4 µg/ml, CompTech, Tyler, 
TX, USA, for 1 h) at 37°C. C4b deposition was detected using 
biotinylated anti­C4 mAb (0.5  µg/ml, HYB 162­02, BioPorto, 
Gentofte, Denmark). Samples were diluted in VBS (5 mM barbi­
tal, 142 mM NaCl, pH 7.4) with 2 mM CaCl2, 1 mM MgCl2, 0.05% 
Tween 20, and 0.1% BSA.
human Tissue samples
Human tissue samples were obtained from the tissue bank at the 
Department of Pathology, Odense University Hospital (Odense, 
Denmark) and derived from surgically removed specimens fixed 
4% phosphate buffered formaldehyde for 12–48 h. Samples were 
conventionally dehydrated, and subsequently embedded in paraf­
fin before sectioning (4–5 µm) and mounting on slides.
immunohistochemistry
Paraffin­embedded, formalin­fixed human tissue sections were 
deparaffinized and rehydrated through serial wash in xylene 
and decreasing concentrations of ethanol. Endogen peroxidase 
activity was blocked by incubation with 1.5% H2O2 for 10 min. 
Antigen retrieval was performed by microwave boiling in 
10 mM Tris base, 0.5 mM EDTA, and pH 9.0 buffer for 15 min. 
The tissue sections were washed in TNT buffer and incubated 
with primary antibodies MAb 16­13 (2 µg/ml), 11­1 (0.5 µg/ml), 
and mouse MAb anti­chicken IgY (1  µg/ml) for 1  h. The tis­
sue sections were washed in TNT buffer and incubated with 
EnVision +  System HRP­labeled polymer (Dako) for 30  min. 
After wash in TNT buffer, the tissue sections were incubated 
with DAB+ (Dako) for 10 min followed by staining with hema­
toxylin. The final immunohistochemical analysis was carried 
out using “multi block” sections comprising the following nor­
mal tissues: the cerebellum, esophagus, fetal and adult liver, gall 
bladder, kidney, large intestine, lung, skeletal muscle, pancreas, 
parotid gland, placenta, prostate, pylorus, spleen, tonsils, thy­
mus, thyroid gland, rectum, small intestine, testis, and urinary 
bladder. The adrenal gland was derived from a patient diagnosed 
with pheochromocytoma.
image acquisition
Histology slides were scanned at 20× (controls) or 40× mag­
nification using a NanoZoomer­XR (Hamamatsu Photonics, 
Japan). Image sections were acquired using NDP.view2 software 
(NanoZoomer Digital Pathology; Hamamatsu Photonics) and 
final JPG images were all uniformly adjusted for color saturation 
(+25) and light (−1) in Adobe Photoshop.
resUlTs
antibody specificity, affinities, and impact 
on complement activation
The reactivity of the applied MAbs was demonstrated by 
Western blotting using serum as source of antigens (Figure 1). 
This analysis showed that the applied MAbs 16­13 (anti­CL­L1) 
and 11­1 (anti­K1) only reacted with protein bands correlating 
with the molecular weight of CL­L1 and CL­K1, respectively 
(Figure 1) (7). There was no cross­reactivity of the two antibod­
ies, and both MAbs recognized all isoforms, ensuring detection 
FigUre 3 | Immunohistochemical localization of CL-K1 and CL-L1 in formalin fixed and paraffin embedded sections of the liver (a,B), kidney (D,e), and lung  
(h,i). Italic letters within images refer to: for the liver h: hepatocytes, ch: centrilobular hepatocytes, and kc: Kupffer cells; kidney g: glomerulus, dt: distal tubules,  
pt: proximal tubules, and bc: Bowman’s capsule; lung I: type I pneumocytes, II: type II pneumocytes, and m: alveolar macrophages. Scale bars in large sections 
and in isotype control sections (c,F,g) correspond to 500 µm and in small sections to 50 µm.
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of all forms of CL­K1 and CL­L1 in the tissue sections. To fur­
ther validate the specificity and reactivity, the two monoclonal 
antibodies were analyzed by SPR using immobilized purified 
collectins and antibodies in fluid phase. MAb16­13 bound to 
CL­L1 (KD =  0.16 ±  0.007  nM, means ±  SD) and to CL­LK 
(KD = 0.14 ± 0.003 nM) but not to CL­K1. MAb 11­1 bound to 
CL­K1 (K1 KD = 5.4 ± 1.8 nM) and to CL­LK (KD = 4.6 ± 1.9 nM) 
but not to CL­L1. Again, cross­reactivity was undetectable and 
binding affinities/avidities were of satisfactory strengths. In the 
characterization of the two applied MAbs, we found that they 
neither interfered with the binding activity of CL­LK to suitable 
ligands nor did they modulate or inhibit the CL­LK­mediated 
complement activation via MASP­2 (Figure 2).
immunohistochemical localization of 
cl-l1 and cl-K1
In the majority of the tested tissues we observed identical 
localization of CL­K1 and CL­L1, both in terms of tissue and 
cell types. Unless the difference in immunoreactivity between 
the two was striking, the co­localization is not commented 
further, neither is the absence of staining of the tissues incu­
bated with isotype matched control antibody. Frequently, the 
immunoreactivity of the CL­K1 MAb (11­1) was stronger than 
that of the CL­L1 MAb (16­13). This may not necessarily reflect 
an increase in CL­K1 quantity in comparison with CL­L1 but 
may originate from the nature of the antibodies (also discussed 
further below).
In the liver, immunoreactivity for CL­K1 and CL­L1 was asso­
ciated with hepatocytes with absent staining of Kupffer cells. 
Staining intensities of CL­L1 was pronounced in the centrilobular 
hepatocytes (Figure 3).
In the kidney, immunoreactivity for CL­K1 and CL­L1 was 
especially associated with the tubular system, with the most 
pronounced staining of the distal tubules (Figure  3), in com­
parison with proximal tubules. CL­L1 immunoreactivity was for 
some distal tubules distinctly associated with the brush border. 
Immunoreactivity for both collectins was also associated with 
the epithelial cells lining the Bowman’s capsules, whereas immu­
noreactivity in the glomerulus itself mainly was associated with 
CL­K1 and only minimally with CL­L1. CL­K1 immunoreactivity 
in the glomerulus was associated morphologically appeared to 
include both podocytes and mesangial cells.
In the lung, CL­K1 immunoreactivity was associated with 
alveolar macrophages, type I and II pneumocytes (Figure  3). 
CL­L1 immunoreactivity appeared only to be associated with 
alveolar macrophages.
FigUre 4 | Immunohistochemical localization of CL-K1 and CL-L1 in formalin fixed and paraffin embedded sections of the thyroid gland (a,B), pancreas  
(D,e), and adrenal gland from a patient diagnosed with pheochromocytoma, (h,i). Italic letters within images refer to: for the thyroid gland tf, thyroid follicles  
and c, parafollicular C cells; pancreas il: islets of Langerhans and a: acinar epithelial cells. Scale bars in large sections and in isotype control sections  
(c,F,g) correspond to 500 µm and in small sections to 50 µm.
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In the thyroid gland, cuboidal epithelial cells lining the base 
membrane of thyroid follicles and parafollicular cells (C­cells) 
were associated with immunoreactivity for both CL­K1 and CL­L1 
(Figure 4). Most pronounced staining was observed for CL­K1.
In the pancreas CL­K1 and CL­L1 immunoreactivity was 
associated with the islets of Langerhans and the pancreatic 
epithelial acinar cells and ducts (Figure 4). Within the islets, 
the vast majority of cells stained positive, indicating for sure 
that insulin­producing cells (beta cells) were associated with 
immunoreactivity and also most likely glucagon­producing 
cells (alpha cells) as well.
In the adrenal tissue section (Figure 4), derived from a patient 
diagnosed with pheochromocytoma, the histology was slightly 
unclear. However, as immunoreactivity for both CL­K1 and 
CL­L1 was associated with nearly all cells, it was deducted that the 
majority of adrenal cells, including both medullary and cortical 
cells, are associated with the two collectins, similar with previous 
findings for the localization of CL­K1 (7).
In the gall bladder, immunoreactivity for both CL­K1 and 
CL­L1 was associated with columnar epithelial cells of the muco­
sal folds, with increasing intensity toward the luminal side of the 
folds (Figure 5). Various cell types in the lamina propria stained 
weakly positive. We observed only scattered staining of cells in 
the muscularis and serosa layers.
In the duodenum, immunoreactivity for CL­K1 and CL­L1 
was associated with epithelial cells in both the mucosa and sub­
mucosa. In the mucosal luminal membrane of the villi, especially 
columnar cells (enterocytes) stained positive (Figure 5). Further 
and intense immunoreactivity of the mucosa was associated with 
the crypts of Lieberkuhn, whereas the muscularis externa was 
only weakly positive for staining. In the submucosa, immuno­
reactivity was associated with cells of the Brunner’s glands.
In the colon, CL­K1 and CL­L1 immunoreactivity was domi­
nantly associated with mucosa and especially with columnar 
epithelial cells in the crypts of Lieberkuhn (tubular glands) 
(Figure 5). In the lamina propria, the staining was scattered and 
associated with various cells types. Within the layers of the mus­
cularis externa and submucosa, staining was also associated with 
endothelial cells, best illustrated for the localization of CL­K1.
In the testis, CL­K1 immunoreactivity was associated with 
germinal epithelial cells lining the tunica propria of the seminif­
erous tubules, spermatogonia (type A and B), and spermatocytes 
(primary and secondary) (Figure 6). These cells were embedded 
in the less immunoreactive Sertoli cells. In the interstitium 
between seminiferous tubules, Leydig cells and endothelial cells 
of capillaries stained weakly positive. CL­L1 immunoreactivity 
was weak in comparison with that of CL­K1, but the pattern of 
the two collectins followed each other.
FigUre 5 | Immunohistochemical localization of CL-K1 and CL-L1 in formalin-fixed and paraffin-embedded sections of the gallbladder (a,B), duodenum  
(D,e), and colon (h,i). Italic letters within images refers to: for the gallbladder s: serosa layer, ms: muscularis layer, m: mucosa layer, lp: lamina propria, ce: 
columnar epithelial cells, and f: fibroblasts; duodenum and colon me: muscularis externica layers, sm: submucosa, mu: mucosa, cl: crypts of Lieberkuhn  
(tubular glands), mm: muscularis mucosa, and v/a: vein/artery. Scale bars in large sections and in isotype control sections (c,F,g) correspond to 500 µm and  
in small sections to 50 µm.
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In the prostate, CL­K1 and CL­L1 immunoreactivity was 
associated with epithelial cells of the prostatic glands, with 
staining of both acini and ducts (Figure  6). The staining was 
associated with both columnar pseudostratified and involuted 
luminal epithelial cells; however, with most intense staining of 
the basal epithelial cells. In the stroma, scattered staining was 
observed in various cells types, including staining of endothelial 
cells. In the ducts, secretory vesicles and concretized material 
stained weakly positive, especially for CL­K1.
In the corpus uterus, CL­K1 and CL­L1 immunoreactivity 
was localized to the epithelial cells in the endometrial glands, 
glandular ducts, and at luminal surface, with comparable stain­
ing of glandular structures in both the stratum functionalis 
(compactum and spongiosum) and stratum basale (Figure  6). 
Both stratified columnar and ciliated cells in the glands stained 
intensely. In the stroma, the immunoreactivity was moderate but 
associated with the majority of cells, with a pronounced staining 
of endothelial cells of the capillaries.
In the skin, CL­K1 and CL­L1 immunoreactivity was associ­
ated with the sweat glands and ducts (Figure 7). CL­K1 staining 
was further associated with the basal layer of the epidermis. In 
the sweat glands and ducts, especially epithelial cells, stained 
positive, while myoepithelial cells only stained weakly positive. 
Within the inner duct, staining was associated with the luminal 
part and eventual content in the duct. Staining of sporadically 
distributed and non­identifiable cells in the dermis was also 
observed.
In the partoid salivary glands, immunoreactivity for CL­L1 
and CL­K1 was associated with both epithelial glandular (acini) 
and epithelial ductal cells (Figure  7). Immunoreactivity was 
localized dominantly to the epithelial cells constituting the 
salivary ducts and less with the secretory acini. However, the 
majority of serous­producing epithelial cells were associated 
with immunoreactivity. Basal epithelial cells of mucin pro ducing 
stained weakly positive. All three kinds of ducts: intercalated 
(minor), intralobulated (striated), and major showed equal 
and dominant immunoreactivity. The immunoreactivity of 
CL­L1 in the salivary serous glands was superior to that of CL­K1.
In the full­term (mature) placenta, CL­K1 and CL­L1 immu­
noreactivity was mainly associated with the syncytiotrophoblast 
layer, at the border of maternal and fetal circulation, and weakly 
with the underlying cytotrophoblasts associated with a villus 
(Figure 7).
Various levels of CL­K1 and CL­L1 immunoreactivity were 
also found to be associated with the following tissues: the thymus, 
spleen, tonsil (Figure S1 in Supplementary Material), esophagus, 
FigUre 6 | Immunohistochemical localization of CL-K1 and CL-L1 in formalin-fixed and paraffin-embedded sections of the testis (a,B), prostate (D,e), and uterus 
corpus (h,i). Italic letters within images refers to: for the testis st: seminiferous tubules, e: endothelial cells, l: Leydig cell, tp: tunicapropria, ge: germinal epithelial 
cells, s: spermatogonia, sy: spermatocytes, and s: spermatids; prostate g: gland, d: duct, c: “concretized” material: a: acininar cells/acinus, s: stroma, and e: basal 
epithelial cells; uterus corpus sb: stratum basale, sf: stratum functionalis, ls: luminal surface, g: gland, d: duct, se: stratified columnar epithelial cells, and ce: 
ciliated epithelial cells. Scale bars in large sections and in isotype control sections (c,F,g) correspond to 500 µm and in small sections to 50 µm.
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stomach (Figure S2 in Supplementary Material), cervix uterus, 
portio uterus, abortus (Figure S3 in Supplementary Material), 
skeletal muscle, cerebellum, and urinary bladder (Figure S4 in 
Supplementary Material). A description of their detailed locali­
zations is provided in the associated figure legends.
cl-K1 and cl-l1 mrna abundancies
To compare protein localization by IHC with site of synthesis 
for the two collectins, data were retrieved from the three major 
RNA expression databases HPA, GTEx, and FANTOM5 RNA. 
For comparison, expression levels were normalized and gradu­
ated into four categories based on a logarithmic division (Tables 
S1 and S2 in Supplementary Material). Levels of immuno­
reactivity were visually validated by three independent persons 
and categorized similarly (Table 1).
mRNA transcripts encoding CL­K1 was detectable in all tested 
tissues and the major sites of synthesis, grouped in the “high” 
category, comprised the adrenals, gallbladder, and liver. In all 
the tested tissues, there was only minimal variance, in terms of 
a single category shift, i.e., “high” to “medium,” between CL­K1 
mRNA levels and immunoreactivity, therefore we considered 
there to be an excellent accordance between site of CL­K1 
synthesis and protein localization. mRNA transcript encoding 
CL­L1 was not detected in as many tissues as CL­K1. Some tis­
sues were categorized with “extremely low/absent” number of 
CL­L1 transcripts. However, by IHC quite a lot of these tissues 
were found to be associated with immunoreactivity, albeit in 
a “low” degree. The major site of CL­L1 mRNA synthesis was 
the liver and placenta and in these tissues the protein was also 
readily detected. Similar to the observations for CL­K1 and 
using the same criteria, there appeared in general to be accord­
ance between site of CL­L1 synthesis and protein localization 
(discussed further below).
To associate the protein localization with an eventual local 
functionality of the two collectins, mediated via the presence 
of MASPs, localization of MASPs (and MAps), and synthesis of 
their respective mRNAs were evaluated by the same approach. 
As the major RNA expression databases currently do not take 
alternatively splicing of the MASP genes into consideration, data 
were retrieved and gathered from the previous work by Thiel and 
colleagues and Garred and colleagues (30–33). MASP­3 expres­
sion appeared to both overlap and being as widely distributed 
as the two collectins, whereas the other MASPs and MAp had 
a restricted pattern of tissue localization, with the liver being a 
tissue of major synthesis and/or detection: an observation, which 
also applied for MBL.
FigUre 7 | Immunohistochemical localization of CL-K1 and CL-L1 in formalin fixed and paraffin embedded sections of the skin (a,B), parotid gland (D,e), and 
placenta (h,i). Italic letters within images refers to: for the skin ed: epidermis, de: dermis, hd: hypodermis, sg: sweat glands, me: myoepithelial cells, and se: 
stratified cuboidal epithelia cells; partoid salivary gland d: duct, ed: epithelial ductal cells, sa: serous acini, ma: mucous acini, mj: major duct, il: intralobulated duct, 
and ic: intercalated duct; placenta v: villus, st: syncytiotrophoblast, ct: cytotrophoblast, and md: mesoderm. Scale bars in large sections and in isotype control 
sections (c,F,g) correspond to 500 µm and in small sections to 50 µm.
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DiscUssiOn
The present work describes the localization of CL­L1 and CL­K1 
in human tissues as determined by immunohistochemistry and 
summarizes further their mRNA tissue profiles derived from 
transcriptome databases. Both CL­L1 and CL­K1 were demon­
strated in epithelial cells in a variety of tissue throughout the 
human body.
Of all the tested MAbs, MAbs 16­13 (anti­CL­L1) and 11­1 
(anti­CL­K1) had the best sensitivity and specificity. The two 
MAbs demonstrated excellent immunoreactivity in the three tis­
sues, the liver, kidney, and adrenals, wherein human CL­K1 and 
CL­L1 localization previously have been demonstrated (6, 7). 
The major positive cell types comprised, hepatocytes, renal 
epithelial cells of tubules, and medullary and cortical cells of 
the adrenals. In addition to the adrenals, tissues from other 
endocrine glands, i.e., pancreas, demonstrated a similar con­
vincing excellent immunoreactivity for both collectins, derived 
from cells in the islets of Langerhans and epithelial cells of the 
ducts. Exocrine tissues of the digestive system comprising the 
gallbladder, duodenum, colon, and also partly the stomach and 
esophagus were also associated with epithelial and mucosal 
immunoreactivity for generally both collectins. Other exocrine 
tissues, comprising sex­specific organs, such as the testis, pros­
tate, and uterus, had also excellent to moderate immunoreactivity 
for both collectins. Among all the analyzed tissues, the testis and 
uterus appeared to be the two tissues with the relative highest 
CL­K1 immunoreactivity. Again, epithelial cells and mucosa in 
the uterus were the major source of immunoreactivity, whereas 
immunoreactivity in testis was associated with germinal epithe­
lial cells of the tubules. Among the tissues analyzed, the highest 
CL­L1 immunoreacti vity was observed in the liver, followed by 
the kidney and parotid gland, wherein immunoreactivity was 
also associated with epithelial cells. Our observation of CL­K1 
synthesis in various tissues falls in line with previous work 
by Wakamiya and colleagues, who by immunofluorescence 
techniques demonstrated partly overlapping localization of 
CL­K1 in murine tissues, using a polyclonal anti­mouse­CL­
K1 antibody (34). In general, we observed a stronger staining 
of CL­K1 than of CL­L1. This may reflect that CL­K1 is more 
abundant than CL­L1, although their levels in the circulation 
are approximately the same (12), or it may simply be a matter of 
affinities of the applied MAbs in combination with availability 
of antigen epitopes on the fixed and embedded tissue sections.
Retrieval and normalization of mRNA levels from three 
transcriptome databases demonstrated accordance between site 
TaBle 1 | Levels of RNA expression: The symbols “+++,” “++,” “+,” and “– ”denote high, medium, low, and absent/extremely low expression, respectively, based on 
the criteria established in Figures S1 and S2 in Supplementary Material.
CL-K1 ihc/ 
rnaa
CL-L1 ihc/ 
rnaa
MASP-1 ihc/ 
rnab
MASP-3 ihc/ 
rnab
MAp44 ihcc/ 
rnad
MASP-2 ihce/ 
rnaf
MAp19 ihce/ 
rnae
MBL ihcg/ 
rnaa
Abortus ++/ +/
Adrenal +++/+++ ++/+ −/−
Cerebellum ++/+ +/− +/ −/−
Cervix uterus ++/+ +/− /+ /+++ /++ /− /− −/−
Colon ++/+ +/− /− /+++ /+ +/− /− −/−
Corpus uterus +++/ +/
Esophagus ++/+ −/− /++ /+ /− /− /− −/−
Fetal liver +/ ++/
Fetal muscle ++/ ++/
Gallbladder +++/+++ ++/+ +/−
Heart /++ /+ /++ /+++ +++/+++ /− /− +/−
Kidney ++/++ ++/+ /++ /++ /− ++/− ++/++ +/−
Liver ++/+++ +++/+++ /+++ /+++ +++/++ +++/+++ +++/+++ +++/+++
Lung ++/+ +/+ /++ /+++ /++ +/+ ++/− −/−
Muscle +/+ −/− /− /+++ ++/+++ /− /− −/−
Pancreas ++/++ +/- /− /+++ /− +/− −/−
Placenta +++/++ +/+++ /++ /+++ /− /− /− −/−
Portio uterus +/ −/
Prostate ++/+ +/+ /− /+++ /− /− +/− −/−
Salivary gland +/+ ++/− −/−
Skin ++/+ +/− −/−
Small intestine ++/++ +/+ /++ /+++ /− /++ /− −/−
Spleen ++/++ +/− /− /++ /− /− /− −/−
Stomach ++/+ +/− +/ +/−
Testis +++/++ +/− /− /++ /− /++ /− −/−
Thymus +/ −/ /− /++ /− /− /−
Thyroid +++/++ +/+ /− /− /− /− +/+++ −/−
Tonsil +/+ −/− −/−
Urinary bladder ++/++ −/+ /− /++ /− /− /− −/−
IHC immunoreactivity levels were judged arbitrarily into the same categories by three independent validations (persons). Missing symbols reflect that the tissue has not been 
analyzed. MASP-1, MASP-3, and Map44 derive all from the MASP1 gene. MASP-2 and MAp19 derive both from the MASP2 gene.
aRelative and normalized data from HPA, GTEx, and FANTOM5 RNA expression databases (Tables S1–S3 in Supplementary Material).
bRelative and normalized data from Seyfarth et al. (30) and Degn et al. (31) (Tables S4 and S5 in Supplementary Material).
cSkjoedt et al. (32).
dRelative and normalized data from Degn et al. (31) and Skjoedt et al. (32) (Table S6 in Supplementary Material).
eDegn et al. (33) (Table S7 in Supplementary Material).
fRelative and normalized data from Seyfarth et al. (30) and Degn et al. (33) (Table S8 in Supplementary Material).
gThe Human Protein Atlas Project (antibody CAB016782).
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of synthesis and protein localization. The only tissue, wherein 
there appeared to be a notable difference, was for CL­L1 in the 
salivary gland. By IHC CL­L1 localization was judged to be 
medium, whereas CL­L1 mRNA appeared to be absent. Other 
CL­L1­specific antibodies showed varying staining of particular 
the salivary gland (data not shown), making us hypothesize that 
the observed disagreement could reflect some sort of uncha­
racterized alternative splicing of CL­L1 in this tissue.
Throughout the IHC staining it was evident that within 
the majority of the tissues, the localization pattern of two col­
lectins was identical; meaning that exactly the same cells in 
a given tissue demonstrated immunoreactivity for both collec­
tins. This is best exemplified when two neighbor sections were 
mounted and processed, as illustrated, e.g., with the corpus 
uterus (Figure  6). Thus, in the majority of tissues there is 
opportunity for the making of CL­LK heteromeric complexes, 
and as previously described, this structure also appears to be 
the most thermodynamic stabile conformation (11). In some 
of the tissues, comprising the thyroid gland, skeletal muscle, 
skin, urinary bladder, and partly the testis and esophagus, 
CL­K1 appeared to be present in large excess in comparison 
with CL­L1, as judged by immunoreactivity; it is likely that 
CL­K1 homomers will be the dominating form in these tis­
sues. The precise distribution of homomers vs. heteromers in 
different tissues should not be judged by immunoreactivity 
and remains thus to be characterized in detail. Although the 
heteromers are eminent in their association with MASP­2 
and C4b deposition, in comparison with the homomers, it is 
worth emphasizing that both types of homomers interact well 
with MASP­1/­3, and may mediate downstream complement 
activation via those alone (8, 11).
To further illustrate the presence of heteromers in different 
tissues we tried to establish a proximity ligation assay using 
antibodies usable on formalin fixed sections but without con­
vincing results. By using purified and fixed CL­LK it appeared 
that even the best combination of antibodies partly shadowed 
for each other in proximity ligation assays and were only 
capable of detecting the very high oligomers of CL­LK, with a 
11
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sensitivity of only 0.2 µg of purified CL­LK per ml immobilized 
onto polylysine­treated object glasses (data not shown).
The overlapping localization of the two collectins in the 
same cells justifies, with a few exceptions, possible assembly 
and presence of the heteromeric CL­LK in most tissues. Based 
on a combination of previous observations and unpublished 
results by our laboratory, it appears that the oligomeric state 
of CL­LK depends on the relative content of CL­L1 and the 
ratio of the CL­K1a/d isotypes (11). As all of our anti­CL­K1 
MAbs recognize the two isotypes equally well, the immunohi­
stochemical results does not per se allow us to deduct any final 
conclusions on the variability of oligomers in different tissues. 
However, tissues with a relative large expression of CL­L1 could 
potentially favor assembly of CL­LK into large oligomers, rang­
ing from 2 to 6 subunits.
We have previously demonstrated that the binding activity of 
CL­K1 and CL­LK, and hence also their complement activating 
ability, in serum/plasma is inhibited by unknown factors (11). 
This has made it difficult to comprehend the role of the two col­
lectins as bona fida activators of complement. In the light of the 
widespread presence of CL­K1 and CL­L1 in various tissues, it is 
possible that binding activity in the periphery, in the absence of 
inhibitory blood components, may be more efficient.
As the hitherto described biological functions of CL­K1 
and CL­L1, in terms of complement activation or involvement 
in embryogenesis, appear to rely on MASPs it is relevant to 
investigate co­localization with MASPs in the periphery. 
However, there is a lack of suitable antibodies specific for the 
three products of the MASP­1 gene, MASP­1/­3, and MAp44, 
but the summarized mRNA profile presented in Table 1 shows 
that MASP­3 synthesis, in contrast with all other MASPs and 
MAps, appears to overlap greatly with the localization of 
CL­K1 and CL­L1. Thus, it is likely that the role of CL­K1 and 
CL­L1 in the periphery is mainly mediated via MASP­3, which 
was recently shown to activate profactor D to factor D, and 
thereby potentiate the alternative pathway and amplification 
loop (35–37). Although (pro) factor D mainly is synthesized 
in adipose tissue (hence the alias “adipsin”) various tissues 
synthesize minor amounts of profactor D, which could be 
a target for MASP­3 in complex with CL­K1/­L1/­LK, and 
thereby potentiate the complement amplification loop in the 
periphery, upon encounter and binding of collectins to suitable 
(microbial) ligands. Alternatively, the two collectins may in the 
periphery, and in parallel with MBL and C1q, exert some of 
their functions by interacting with the metalloproteases bone 
morphogenic protein 1 and tolloid­like proteases, involved in 
extracellular matrix assembly and growth factor signaling (38). 
Interactions between CL­K1, ­L1, or ­LK with these metallo­
proteases remain to be investigated.
In the light of our (co­)localization of CL­K1 and CL­L1 to 
peripheral tissues it appears that the previously focus on their 
roles in the circulation, liver, and kidney, may have disparaged a 
compelling localization in especially exocrine/endocrine tissues 
and mucosa, suggestive of that CL­L1, CL­K1, and CL­LK may 
play roles on epithelial surfaces in general and in tissue characte­
rized by a high degree of exocytosis. The localization of CL­K1 
and CL­L1 reminds also in many ways of the localization of the 
collectin surfactant protein D (39).
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